Literature DB >> 2492787

The polycystic ovary syndrome: pathogenesis and treatment.

R Barnes1, R L Rosenfield.   

Abstract

PURPOSE: To propose a theory for the pathogenesis of the polycystic ovary syndrome that explains the endocrinologic abnormalities of the syndrome and provides a rational approach to therapy. DATA IDENTIFICATION: An English-language literature search using MEDLINE (1975 to 1988) and extensive bibliographic reviews of identified articles. STUDY SELECTION: We reviewed the literature and selected 169 articles considered most relevant for the definition of the endocrinologic abnormalities, elucidation of pathogenic mechanisms, or delineation of therapeutic interventions. DATA EXTRACTION: The authors independently assessed study quality and data concerning endocrinologic abnormalities, pathogenic mechanisms, and therapy of the polycystic ovary syndrome. RESULTS OF DATA SYNTHESIS: The polycystic ovary syndrome may be best defined as functional, gonadotropin-dependent ovarian hyperandrogenism. The polycystic ovary syndrome results when a primary defect increases one of three variables: the ratio of the serum concentrations of luteinizing hormone to follicle stimulating hormone, the ratio of the intraovarian concentrations of androgen to estrogen, or follicular atresia. An increase in one of these variables can then induce successive abnormalities in one or more of the remaining two variables in a to-and-fro manner.
CONCLUSIONS: Evidence suggests that several causes exist, each of which can produce the clinical syndrome by a to-and-fro interaction among pathogenic mechanisms. Treatment objectives for the syndrome include amelioration of hirsutism, induction of ovulation, and weight reduction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492787     DOI: 10.7326/0003-4819-110-5-386

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  Hirsutism: pilosebaceous unit dysregulation. Role of peripheral and glandular factors.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

2.  A two-dimensional electrophoresis reference map of human ovary.

Authors:  Lei Wang; Ye-Fei Zhu; Xue-Jiang Guo; Ran Huo; Xiang Ma; Min Lin; Zuo-Min Zhou; Jia-Hao Sha
Journal:  J Mol Med (Berl)       Date:  2005-07-15       Impact factor: 4.599

Review 3.  Polycystic ovary syndrome: What is it? Pathogenetic enigma and therapeutic dilemma.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

4.  Comparison between buserelin and dexamethasone testing in the assessment of hirsutism.

Authors:  T Re; L Barbetta; C Dall'Asta; G Faglia; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

5.  Androgen-producing bilateral large cortical adrenal adenomas associated with polycystic ovaries in a young female.

Authors:  D Micić; S Zorić; V Popović; R Janković; M Jancić; R Han; D Manojlović; J Mićić
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

Review 6.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

Review 7.  Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis.

Authors:  J M Goldman; L J Kapadia
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

8.  Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells.

Authors:  J F Cara; J Fan; J Azzarello; R L Rosenfield
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

9.  Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors.

Authors:  A Vidal-Puig; M Muñoz-Torres; E Jodar-Gimeno; C García-Calvente; P Lardelli; M E Ruiz-Requena; F Escobar-Jiménez
Journal:  Clin Investig       Date:  1994-11

Review 10.  The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies.

Authors:  R B Barnes
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.